BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/5/2014 2:31:00 PM | Browse: 386 | Download: 327
Publication Name World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID 4067
Country of Manuscript Source Canada
Received
2013-06-13 09:13
Peer-Review Started
2013-06-13 09:43
To Make the First Decision
2013-06-24 10:22
Return for Revision
2013-07-04 15:57
Revised
2013-07-08 21:51
Second Decision
2013-07-18 17:56
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-07-19 02:31
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-09-22 18:16
Publish the Manuscript Online
2013-11-04 12:31
ISSN 2150-5349 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Minireviews
Article Title Non-dietary forms of treatment for adult celiac disease
Manuscript Source Invited Manuscript
All Author List Hugh James Freeman
Funding Agency and Grant Number
Corresponding author Hugh James Freeman, Professor, Department of Medicine (Gastroenterology), University of British Columbia Hospital, 2211 Wesbrook Mall, Vancouver, BC V6T 1W5, Canada. hugfree@shaw.ca
Keywords Adult celiac disease; Gluten-free diet; Non-dietary treatment of celiac disease; Tight junction inhibition; Protease; Immunotherapy; Vaccination
Core Tip Non-dietary forms of treatment for adult celiac disease are currently being evaluated and some have reached clinical trials. Some novel approaches being investigated include hydrolysis of gliadin peptides, inhibition of intestinal permeability, blockade of T lymphocytes and transglutaminase 2/human leukocyte antigen-DQ2 functions as well as induction of immune tolerance. Future evaluations will need to define effects on specific endpoints and ensure an improvement in symptoms, laboratory test results and, most important, mucosal inflammatory changes. Therapeutic trials with novel agents will be difficult from an ethical perspective as the current form of management with a gluten-free diet already provides an excellent result for most compliant patients with celiac disease. Finally, effects on other known superimposed diseases will need close evaluation (i.e., lymphoproliferative and other malignancies).
Publish Date 2013-11-04 12:31
Citation Freeman HJ. Non-dietary forms of treatment for adult celiac disease. World J Gastrointest Phar-macol Ther 2013; 4(4): 108-112
Url http://www.wjgnet.com/2150-5349/full/v4/i4/108.htm
DOI http://dx.doi.org/10.4292/wjgpt.v4.i4.108
Full Article (PDF) WJGPT-4-108.pdf
Manuscript File 4067-Review.doc
Answering Reviewers 4067-Answering reviewers.pdf
Copyright License Agreement 4067-Copyright assignment.pdf
Peer-review Report 4067-Peer reviews.pdf
Scientific Editor Work List 4067-Scientific editor work list.doc